Compare · ADOC vs TECH
ADOC vs TECH
Side-by-side comparison of Edoc Acquisition Corp. (ADOC) and Bio-Techne Corp (TECH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADOC and TECH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- TECH is the larger of the two at $8.48B, about 70.1x ADOC ($121.0M).
- TECH has hit the wire 6 times in the past 4 weeks while ADOC has been quiet.
- TECH has more recent analyst coverage (22 ratings vs 0 for ADOC).
- Company
- Edoc Acquisition Corp.
- Bio-Techne Corp
- Price
- $2.81-63.97%
- $54.19+3.79%
- Market cap
- $121.0M
- $8.48B
- 1M return
- -
- +2.81%
- 1Y return
- -
- +7.82%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 22
Edoc Acquisition Corp.
Edoc Acquisition Corp. is a blank check company. The company intends to focus on businesses primarily operating in the health care and health care provider space in North America and the Asia-Pacific. Edoc Acquisition Corp. was incorporated in 2020 and is based in Victor, New York.
Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Latest ADOC
- SEC Form 15-12G filed by Edoc Acquisition Corp.
- Edoc Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form 25-NSE filed by Edoc Acquisition Corp.
- Edoc Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 425 filed by Edoc Acquisition Corp.
- SEC Form 425 filed by Edoc Acquisition Corp.
- Edoc Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits
- Edoc Acquisition Corp. Announces Postponement Of Special Meeting Of Shareholders On Proposed Business Combination
- Edoc Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits
- SEC Form 425 filed by Edoc Acquisition Corp.
Latest TECH
- Chief Executive Officer Kelderman Kim converted options into 11,344 shares and covered exercise/tax liability with 1,363 shares, increasing direct ownership by 19% to 63,058 units (SEC Form 4)
- CFO Hippel James covered exercise/tax liability with 56,097 shares and converted options into 62,000 shares, increasing direct ownership by 4% to 148,625 units (SEC Form 4)
- SEC Form 4 filed by Kelderman Kim
- Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity
- Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results
- SEC Form 4 filed by Bohnen Shane
- Amendment: SEC Form SCHEDULE 13G/A filed by Bio-Techne Corp
- Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite
- SEC Form 4 filed by President - Diag & Spatial Bi Crouse Steven C.
- New insider Crouse Steven C. claimed ownership of 5,894 shares (SEC Form 3)